{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:59:47Z","timestamp":1791845987934,"version":"4.3.4"},"reference-count":119,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The emergence of antimicrobial resistance against\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    , the leading cause of mortality due to a single microbial pathogen worldwide, represents a growing threat to public health and economic growth. The global burden of multidrug\u2010resistant tuberculosis (MDR\u2010TB) has recently increased by an annual rate of more than 20%. According to the World Health Organization approximately only half of all patients treated for MDR\u2010TB achieved a successful outcome. For many years, patients with drug\u2010resistant tuberculosis (TB) have received standardized treatment regimens, thereby accelerating the development of MDR\u2010TB through drug\u2010specific resistance amplification. Comprehensive drug susceptibility testing (phenotypic and\/or genotypic) is necessary to inform physicians about the best drugs to treat individual patients with tailor\u2010made treatment regimens. Phenotypic drug resistance can now often, but with variable sensitivity, be predicted by molecular drug susceptibility testing based on whole genome sequencing, which in the future could become an affordable method for the guidance of treatment decisions, especially in high\u2010burden\/resource\u2010limited settings. More recently, MDR\u2010TB treatment outcomes have dramatically improved with the use of bedaquiline\u2010based regimens. Ongoing clinical trials with novel and repurposed drugs will potentially further improve cure\u2010rates, and may substantially decrease the duration of MDR\u2010TB treatment necessary to achieve relapse\u2010free cure.\n                  <\/jats:p>","DOI":"10.1111\/resp.13304","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T16:41:25Z","timestamp":1523464885000},"page":"656-673","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":220,"title":["Drug\u2010resistant tuberculosis: An update on disease burden, diagnosis and treatment"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"first","affiliation":[{"name":"Division of Clinical Infectious Diseases Research Center Borstel Borstel Germany"},{"name":"German Center for Infection Research (DZIF), TTU\u2010TB, Borstel, Germany"},{"name":"International Health\/Infectious Diseases University of L\u00fcbeck L\u00fcbeck Germany"},{"name":"Department of Medicine Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Chesov","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Diseases Research Center Borstel Borstel Germany"},{"name":"Department of Pneumology and Allergology State University of Medicine and Pharmacy \u201cNicolae Testemitanu\u201d Chisinau Republic of Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Diseases Research Center Borstel Borstel Germany"},{"name":"German Center for Infection Research (DZIF), TTU\u2010TB, Borstel, Germany"},{"name":"International Health\/Infectious Diseases University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9699-9730","authenticated-orcid":false,"given":"Chi C.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Health Tuberculosis and Chest Service, Centre for Health Protection Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarir","family":"Udwadia","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Hinduja Hospital and Research Centre Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-5341","authenticated-orcid":false,"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[{"name":"Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine University of Cape Town Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,11]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"The WHO End TB Strategy","author":"World Health Organization","year":"2015"},{"key":"e_1_2_12_3_1","unstructured":"G20 Leaders\u2019 Declaration. Shaping an interconnected world 2017. Available from URL:https:\/\/www.g20.org\/gipfeldokumente\/G20-leaders-declaration.pdf"},{"key":"e_1_2_12_4_1","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2017"},{"key":"e_1_2_12_5_1","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2010"},{"key":"e_1_2_12_6_1","unstructured":"SharmaA HillA KurbatovaE van derWaltM KvasnovskyC TupasiTE CaoiliJC GlerMT VolchenkovGV KazennyyBYet al.;Global Preserving Effective TBTSI. Estimating the future burden of multidrug\u2010resistant and extensively drug\u2010resistant tuberculosis in India the Philippines Russia and South Africa: a mathematical modelling study.Lancet Infect. Dis.2017;17:707\u201315."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30433-7"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201512-845OC"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0838"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0110"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70130-0"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0083"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604544"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2878"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079310"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30188-2"},{"key":"e_1_2_12_17_1","volume-title":"Equity, social determinants and public health programmes","author":"World Health Organization","year":"2010"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12156"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30079-6"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir658"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis353"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_2_12_23_1","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20101986, with relevant subsequent publications","volume":"3","author":"Fox W","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_12_24_1","first-page":"CD003343","article-title":"Directly observed therapy for treating tuberculosis","author":"Karumbi J","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_12_25_1","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health\u2010care settings, 2005","volume":"54","author":"Jensen PA","year":"2005","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.25.3.243-248.1961"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201107-1190OC"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009593.pub2"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02268-10"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60438-8"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907847"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00007814"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguezJ BoettgerEC CirilloD CobelensF EisenachKD GagneuxS HillemannD HorsburghR Molina\u2010MoyaB NiemannSet al.;TBNET;RESIST\u2010TB networks. Clinical implications of molecular drug resistance testing forMycobacterium tuberculosis: a TBNET\/RESIST\u2010TB consensus statement.Int. J. Tuberc. Lung Dis.2016;20:24\u201342.","DOI":"10.5588\/ijtld.15.0221"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00812-17"},{"key":"e_1_2_12_35_1","first-page":"CD009593","article-title":"Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","author":"Steingart KR","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-280"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01075-2016"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01144-16"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-59"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02597-13"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200610"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0519"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03614-14"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00466-X"},{"key":"e_1_2_12_45_1","first-page":"1","article-title":"Whole\u2010genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study","volume":"3099","author":"Walker TM","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1413930"},{"key":"e_1_2_12_47_1","unstructured":"World Health Organization. Largest ever roll\u2010out of GeneXpert\u00aerapid TB test machines in 21 countries 2013. [Accessed 1 April 2018] Available from URL:http:\/\/www.who.int\/tb\/features_archive\/xpertprojectlaunch\/en\/"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30691-6"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30474-7"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-17"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614915"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00089808"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02483-16"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03073-14"},{"key":"e_1_2_12_55_1","unstructured":"BrownAC BryantJM Einer\u2010jensenK HounietDT ChanJZM DepledgeDP NikolayevskyyV BrodaA StoneMJ MetteT MelzerM RosmarinC McHugh TD ShortenRJ.Rapid Whole Genome Sequencing ofM. tuberculosisdirectly from clinical samples.2015;44."},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep46327"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00025-15"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0221"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201703-0556OC"},{"key":"e_1_2_12_60_1","unstructured":"World Health Organization. WHO treatment guidelines for drug\u2010resistant tuberculosis. 2016 update. World Health Organization Document. 2016; WHO\/HTM\/TB\/2016.04: 1\u201359."},{"key":"e_1_2_12_61_1","unstructured":"World Health Organization. Guidelines for the programmatic management of drug\u2010resistant tuberculosis. 2011 update. World Health Organization Document. 2011; WHO\/HTM\/TB\/2011.6: 1\u201333."},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100"},{"key":"e_1_2_12_64_1","volume-title":"Guidelines for the programmatic management of drug\u2010resistant tuberculosis 2016 update","author":"World Health Organization","year":"2016"},{"key":"e_1_2_12_65_1","unstructured":"The International Union against Tuberculosis and Lung Diseases. STREAM clinical trial results provide vital insight into nine\u2010month treatment regimen for multidrug\u2010resistant tuberculosis 2017. Available from URL:https:\/\/www.theunion.org\/news-centre\/news\/stream-clinical-trial-results-provide-vital-insight-into-nine-month-treatment-regimen-for-multidrug-resistant-tuberculosis"},{"key":"e_1_2_12_66_1","doi-asserted-by":"crossref","unstructured":"LangeC DuarteR Frechet\u2010JachymM G\u00fcntherG GuglielmettiL OlaruID OliveiraO RumetshoferR VezirisN vanLethF;European MDR\u2010TB database collaboration. Limited benefit of the new shorter multidrug\u2010resistant tuberculosis regimen in Europe.Am. J. Respir. Crit. Care Med.2016;194:1029\u201331.","DOI":"10.1164\/rccm.201606-1097LE"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209841"},{"key":"e_1_2_12_68_1","article-title":"Eligibility for shorter treatment of multidrug\u2010resistant tuberculosis in the European Union","volume":"49","author":"Werf MJ","year":"2017","journal-title":"Eur. Respir. J."},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02445-2016"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01967-2016"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00753-2017"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"e_1_2_12_75_1","doi-asserted-by":"crossref","unstructured":"GuglielmettiL Le DuD VezirisN CaumesE Marigot\u2010OuttandyD YazdanpanahY RobertJ Frechet\u2010JachymM; Mycobacteria M\u2010TMGotFNRCf; the Physicians of the French MDRTBC. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug\u2010resistant tuberculosis?Eur. Respir. J.2016;48:582\u20135.","DOI":"10.1183\/13993003.00411-2016"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00742-2017"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00387-2017"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00120-13"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00388-13"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.051"},{"key":"e_1_2_12_83_1","doi-asserted-by":"crossref","unstructured":"FoxGJ BenedettiA CoxH KohWJ ViikleppP AhujaS PasvolG MenziesD;Collaborative Group for Meta\u2010Analysis of Individual Patient Data in MDR\u2010TB. Group 5 drugs for multidrug\u2010resistant tuberculosis: individual patient data meta\u2010analysis.Eur. Respir. J.2017;49:1600993.","DOI":"10.1183\/13993003.00993-2016"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug\u2010resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang S","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1513236"},{"key":"e_1_2_12_86_1","unstructured":"ConradieF DiaconA EverittD MendelC vanNiekerkC HowellP CominsK SpigelmanM. The NIX\u2010TB trial of pretomanid bedaquiline and linezolid to treat XDR\u2010TB. .Conference on Retroviruses and Opportunistic Infections (CROI2017) Seattle 2017; Abstract 80LB."},{"key":"e_1_2_12_87_1","unstructured":"STAT DT. Implications for the field of the recent results from the first\u2010ever phase III trials for multidrug\u2010resistant TB 2017. [Accessed 19 Nov 2017.] Available from URL:https:\/\/www.ghdonline.org\/uploads\/Updated_November_12_2017_STAT_phaseIII_Union_summary.pdf"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13143"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0944"},{"key":"e_1_2_12_90_1","doi-asserted-by":"crossref","unstructured":"PymAS DiaconAH TangSJ ConradieF DanilovitsM ChuchottawornC VasilyevaI AndriesK BakareN De MarezT Haxaire\u2010TheeuwesM LounisN MeyvischP Van BaelenB vanHeeswijkRP DannemannB;TMC207\u2010C209 Study Group. Bedaquiline in the treatment of multidrug\u2010 and extensively drug\u2010resistant tuberculosis.Eur. Respir. J.2016;47:564\u201374.","DOI":"10.1183\/13993003.00724-2015"},{"key":"e_1_2_12_91_1","volume-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision","author":"World Health Organization","year":"2013"},{"key":"e_1_2_12_92_1","first-page":"2014","volume-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014)","author":"World Health Organization"},{"key":"e_1_2_12_93_1","unstructured":"GuntherG LangeC AlexandruS AltetN AvsarK BangD BarbutaR BothamleyG CiobanuA CruduVet al.;for TBNET. Treatment outcomes in multidrug\u2010resistant tuberculosis.N. Engl. J. Med.2016;375:1103\u20135."},{"key":"e_1_2_12_94_1","doi-asserted-by":"crossref","unstructured":"Magis\u2010EscurraC GuntherG LangeC AlexandruS AltetN AvsarK BangD BarbutaR BothamleyG CiobanuAet al.;for TBnet. Treatment outcomes of MDR\u2010TB and HIV co\u2010infection in Europe.Eur. Respir. J.2017;49 1602363.","DOI":"10.1183\/13993003.02363-2016"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00036-3"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2141OC"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02122-2017"},{"key":"e_1_2_12_98_1","doi-asserted-by":"crossref","unstructured":"G\u00fcntherG vanLethF AlexandruS AltetN AvsarK BangD BarbutaR BothamleyG CiobanuA CruduV DavilovitsM DedicoatM DuarteR GualanoG KunstH deLangeW LeimaneV Magis\u2010EscurraC McLaughlinAM MuylleI PolcovaV PontaliE PopaC RumetshoferR SkrahinaA SolodovnikovaV SpinuV TiberiS ViikleppP LangeC;Tbnet. Multidrug\u2010resistant tuberculosis in Europe 2010\u20102011.Emerg. Infect. Dis.2015;21:409\u201316.","DOI":"10.3201\/eid2103.141343"},{"key":"e_1_2_12_99_1","doi-asserted-by":"crossref","unstructured":"G\u00fcntherG vanLethF AltetN DedicoatM DuarteR GualanoG KunstH MuylleI SpinuV TiberiSet al.;Tbnet. Beyond multidrug\u2010resistant tuberculosis in Europe: a TBNET study.Int. J. Tuberc. Lung Dis.2015;19:1524\u20137.","DOI":"10.5588\/ijtld.15.0274"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30423-4"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv354"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449037"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0363PP"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ610"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw164"},{"key":"e_1_2_12_106_1","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug\u2010resistant tuberculosis","volume":"61","author":"Altena R","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01054-12"},{"key":"e_1_2_12_108_1","unstructured":"AhujaSD AshkinD AvendanoM BanerjeeR BauerM BayonaJN BecerraMC BenedettiA BurgosMet al.;Collaborative Group for Meta\u2010Analysis of Individual Patient Data in MDR\u2010TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta\u2010analysis of 9 153 patients.PLoS Med.2012;9:e1001300."},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2017.08.004"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046191"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036886"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0310"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4177"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw002"},{"key":"e_1_2_12_115_1","doi-asserted-by":"crossref","unstructured":"HarrisRC KhanMS MartinLJ AllenV MooreDA FieldingK GrandjeanL;LSHTM MDR\u2010TB Surgery Systematic Review Group. The effect of surgery on the outcome of treatment for multidrug\u2010resistant tuberculosis: a systematic review and meta\u2010analysis.BMC Infect. Dis.2016;16:262.","DOI":"10.1186\/s12879-016-1585-0"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70033-5"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201705-0936OC"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62675-6"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505196"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00803-2016"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.13304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:06:08Z","timestamp":1751544368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,11]]},"references-count":119,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/resp.13304"],"URL":"https:\/\/doi.org\/10.1111\/resp.13304","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,11]]},"assertion":[{"value":"2017-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}